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Spinal cord injury (SCI) and spinal infarction lead to neurological complications and
eventually to paraplegia or quadriplegia. These extremely debilitating conditions are
major contributors to morbidity. Our understanding of SCI has certainly increased during
the last decade, but remains far from clear. SCI consists of two defined phases:
the initial impact causes primary injury, which is followed by a prolonged secondary
injury consisting of evolving sub-phases that may last for years. The underlying
pathophysiological mechanisms driving this condition are complex. Derangement
of the vasculature is a notable feature of the pathology of SCI. In particular,
an important component of SCI is the ischemia-reperfusion injury (IRI) that leads
to endothelial dysfunction and changes in vascular permeability. Indeed, together
with endothelial cell damage and failure in homeostasis, ischemia reperfusion injury
triggers full-blown inflammatory cascades arising from activation of residential innate
immune cells (microglia and astrocytes) and infiltrating leukocytes (neutrophils and
macrophages). These inflammatory cells release neurotoxins (proinflammatory cytokines
and chemokines, free radicals, excitotoxic amino acids, nitric oxide (NO)), all of which
partake in axonal and neuronal deficit. Therefore, our review considers the recent
advances in SCI mechanisms, whereby it becomes clear that SCI is a heterogeneous
condition. Hence, this leads towards evidence of a restorative approach based on
monotherapy with multiple targets or combinatorial treatment. Moreover, from evaluation
of the existing literature, it appears that there is an urgent requirement for multi-centered,
randomized trials for a large patient population. These clinical studies would offer an
opportunity in stratifying SCI patients at high risk and selecting appropriate, optimal
therapeutic regimens for personalized medicine.
Keywords: inflammation, ischemia-reperfusion injury (IRI), spinal cord injury (SCI), reactive oxygen species (ROS),
leukocytes, glia, therapeutics
INTRODUCTION
Spinal cord injury (SCI) remains a major cause of disability (Singh et al., 2014). This debilitating
event is a principal life-changer of previously-healthy individuals. Not only does it drain limited
health-care budgets, but it also influences the psyche of the subjects. Likewise, SCI impacts the
social demands put in place to ameliorate the well-being of the incapacitated individual. This
is because it often involves immediate and extended family members and friends. Since the
times of the Egyptian Pharaohs, SCI has been an area of neglect in relation to pharmacological
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research for the simple fact that it was considered to be terminal,
and that surgery is the sole option (Silva et al., 2014). Currently,
there is a realization that if rapid intervention is applied, then
SCI is definitely treatable, and the SCI-associated high rates of
mortality can be reduced (Garshick et al., 2005; Silva et al., 2014).
This offers a glimmer of hope for patients and society at large. A
consequential sequence of SCI is the significant neurological or
psychological deficit, which obviously contributes to the overall
burden of this condition. This results in reduced life span, loss of
productive years, and steep health care costs. Since SCI is ranked
as the most calamitous cause of morbidity, it does not come as
surprising that the total costs are staggering. In Spain, $131 to 302
million for 2007 were spent to deal with this debilitation (García-
Altés et al., 2012), whereas the outlay in Canada is estimated to
be Canadian $2.7 billion for 1389 new patients per year (Krueger
et al., 2013). The annual expenditure for American citizens
suffering from SCI-related disabilities is in excess of $10 billion
(Wilt et al., 2008).
Mention must be made of incidence of SCI that occurs as
a complication arising from surgery for thoracic or abdominal
aortic aneurysms during the procedure to repair the damaged
aorta (Hollier et al., 1992). Prolonged aortic cross-clamping or
ligation of intercostal or lumber arteries proceeds to spinal cord
ischemia. This can affect the thoracic, lumbar or sacral regions,
and may lead to paraplegia (hindlimb paralysis; Bicknell et al.,
2009; Shimizu and Yozu, 2011). Victims of motor vehicle
accidents, war- or combat-related injuries, frail elderly subjects
who fall, and individuals with gunshot wounds may also suffer
from paraplegia, or even quadriplegia attributable to neurological
problems (Smith et al., 2005; Blair et al., 2012; Schoenfeld et al.,
2013; Singh et al., 2014). Horseback riding (Lin et al., 2011),
high contact sports like ice hockey, American football and rugby
(scrummage, tackles and rucks) place players at risk of injuries
to the cervical spine, which occur at 4th, 5th and 6th vertebrae
with hyperextension, hyperflexion or axial loading (Quarrie
et al., 2002; Rihn et al., 2009). As a consequence of the high
impact collisions, the damages result in a spectrum of traumatic
injuries, from complete recovery at one end, to partial/complete
paraplegia or tetraplegia, to death at the other extreme end (Singh
et al., 2014; Valparaiso et al., 2015).
Spinal cord injuries (SCI) can be classified into primary and
secondary. Primary SCI often results frommechanical impaction
to the spine, concomitant with or followed by compression,
contusion, stretching or kinking of the spinal cord (Stahel
et al., 2012; Table 1). Secondary SCIs refers to the multifaceted
pathological mechanisms that start after primary SCIs and can
last up to weeks (Wilson et al., 2013). These events include,
but are not limited to, breakdown of blood-spinal cord barrier
(BSCB), neuroinflammation, oxidative stress, neuronal injury,
and ischemic dysfunction (Table 1). SCIs are also associated
with other functional problems, including neuropathic pain
and autonomic dysfunction, causing incontinence of bladder,
rectum and anus (lower gastrointestinal tract), as well as
impotence (Rosenzweig and McDonald, 2004; Singh et al.,
2014). Therefore, the pathophysiology of SCI consists of
a primary injury along with sequential secondary damages
emanating from multi-cascade of patho-mechanisms. These
secondary pathologic series of events lead to further damages
to the SC.
Together, these bio-reactions drive a homeostatic imbalance
leading to an inflammatory milieu that is linked to hemostatic
and metabolic changes (Guízar-Sahagún et al., 2004) as well
as hemodynamic alterations in the pathophysiology of SCI. In
the present review, these will be highlighted, along with a prior
description of available animal models for investigation.
ANIMAL MODELS FOR SCI
At the outset, it is important to realize that SCI in man is
heterogeneous in nature. Diverse animal species (rats, mice,
sheep, rabbits, dogs, opossums and baboons) have been used to
simulate SCI. Compared to other models, the rat offers several
advantages such as its moderate cost, vascular anatomy andmore
importantly, its physiology which is rather highly comparable
to humans’. Moreover, the dimension of isolated arteries is
manageable for investigating vascular function. The SC and
surrounding tissue are of reasonable size. In a 280 gm rat, the
total blood volume is almost 16 ml, and approximately 10 ml of
blood can be obtained for hematological studies (Akhtar et al.,
2008; Choo et al., 2008; Cheriyan et al., 2014).
Specific therapeutic modalities have been applied to mitigate
the induced SCI in animal models. However, to date, the
translation of these promising outcomes from the lab to
the bedside has been without success (Martirosyan et al.,
2011; Varma et al., 2013). The type of SCI most frequently
induced is dependent on the mechanical impact of the injury
which can then be categorized into: compression, contusion,
distraction, dislocation, transection, collagenase and ischemia-
reperfusion (interruption of blood flow) injury (IRI; Choo et al.,
2007, 2008, 2009; Akhtar et al., 2008; Rummery et al., 2010;
Cheriyan et al., 2014; Losey and Anthony, 2014; Kato et al.,
2015; Figure 1). Each of these models bears many advantages,
but is not without some limitations (Akhtar et al., 2008; Choo
et al., 2008; Rummery et al., 2010; Cheriyan et al., 2014; Losey
and Anthony, 2014). For example, the ischemia-reperfusion SCI
injury model may lead to aortic cross-clamping resulting in
several complications. Some contusion models suffer from some
weakness such as the clamping technique (in infinite horizon,
force-controlled contusion) or imprecise duration of impact (in
MASCIS weight-drop contusion approach). Many compression
models may also suffer from the absence of recording injury
parameters. Inconsistent reproducibility or uncommon clinical
SCI type are major limitations of partial or complete transection
models, respectively. It must be stressed that most human SCIs
involve compressive and contusive injury. The aforementioned
references elaborate on details of following models.
Distraction
Cranial-caudal distraction between C4-C5, edema (no
overt hemorrhage), axonal damage, demyelination, gliosis,
rostrally-stretched nodes of Ranvier.
Advantages/disadvantages: in humans, a significant
proportion of injuries are located in cervical region of the
spine.
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TABLE 1 | Summary of temporal sequence of pathophysiological events during SCI phases, primary and secondary.
Primary Secondary
Immediate (<2 h) Acute (<2 days) Intermediate (<2 weeks) Chronic (weeks/months)
Mechanical injury:
compression, contusion
Commencement of innate immunity:
microglia activation and neutrophil
infiltration
Full-blown inflammation: innate
immune response (monocytes,
macrophages M1, microglia
M1& reactive astrocytes) and
adaptive immunity (T and B cells)
Wallerian degeneration: cytoskeleton
disintegration, loss of cell membrane,
axon fragmentation
Hemodynamic instability Release of inflammatory mediators:
pro-inflammatory cytokines (IL-1, IL-6,
TNF-α IFN-γ) and chemokines
(CXCL1, CXCL12)
Apoptosis of oligodendrocytes Apoptosis of oligodendrocytes
Vasospasm Oxidative stress: increased expression
of iNOS; elevated levels of free radicals,
ROS, RNS, and NO; increased lipid
peroxidation
Demyelination Demyelination: fragmentation of myelin,
cellular debris
Reduced blood flow Glutaminergic excitotoxicity: cell damage,
depolarization
Initiation of cyst formation Glial scar maturation
Hemorrhage Metabolic derangement: ionic imbalance
(Na+, K+, Cl−, Ca2+); acidosis; ATP,
decreased O2 and glucose
Neuropathic pain Cavitation
Edema Mitochondrial damage: pore formation;
cyt c release
Glial scar initiation Lesion stabilization
Alteration of vascular
structure
Cytoskeletal damage Chemokine release: CXCL1,
CXCL9, CXCL10, CXCL12
Chemokine release: CXCL12
Ischemic necrosis Apoptosis Phagocytosis: RBCs, myelin
and neutrophils
Neuron growth inhibitors: Nogo,
MAG, ROCK
Thrombosis Demyelination Resolution/Repair: resolution of
edema; Repair of BSCB
Repair/ Recovery/ Resolution/
Regeneration neuronal sprouting,
Regeneration of axon clusters,
Complement- dependent,
Neuro- reparatory processes,
Change to anti-inflammatory phenotype
of microglia and macrophages (M2)
Destruction of neural tissue Neuronal cell death
Activation of microglia Neurogenic shock
Axonal shearing BSCB permeability
Neuronal cell death Complement-activated neurodegradation
Myelin debris: release
of DAMPs
Release of proteases:
MMPs, calpain, caspases
Evidence of complement
protein C3
Mechanical-derived primary damage is followed by a prolonged secondary injury consisting of overlapping, different phases. This involves interplay of infiltrating leukocytes
and residential parenchymal cells (adaptive and innate immunity), and their releasates (inflammatory cytokines and chemokines, anti-inflammatory cytokines).
Compression
Significant vascular injury (hemorrhagic necrosis,
hypoperfusion), neuronal ischemia, neurological derangement.
Advantages/disadvantages: one of the most commonly used
procedures to investigate SCI.
Dislocation
C4/C5 dorso-ventral dislocation, substantial axonal degeneration
(axolemma stretched rostrally), deformation in node of Ranvier
at epicenter of injury, vascular damage in gray matter, extended
lesion in dorsal corticospinal tract, activated astrocytes and
microglial (cells reactive bi-directionally: cranial to caudal),
apoptosis (cytochrome C (cyt c) release from mitochondria in
penumbra).
Advantages/disadvantages: again this technique examines the
injury in cervical region of SC.
Contusion
Widespread tissue pathology, extending both rostrally and
caudally from epicenter of injury—disruption of white and
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FIGURE 1 | An overview of rat models of Spinal cord injury (SCI). The principle site of injury is the dorsal thoracic spine, and the dorsal spinal artery.
gray matter, intraparenchymal hemorrhage, hypotension,
bradycardia, cellular debris, diffuse axonal injury, glia activation
with cavities and fluid-filled cysts, apoptosis of oligodendrocytes,
macrophage infiltration and activated microglial at epicenter,
distortion of nodes of Ranvier.
Advantages/disadvantages: the most widely used method for
investigating SCI.
Ischemia-Reperfusion Injury
Vascular derangement (ischemia, hypoxia, vasospasms,
thrombosis), neuronal damage, lesion cavity.
Advantages/disadvantages: no mechanical trauma to SC,
pathology not consistently reproducible.
Transection of Spinal Cord
Tissue pathology focused at epicenter of injury—white matter
apoptosis, demyelination, macrophage infiltration and microglia
activation at epicenter.
Advantages/disadvantages: rare in humans; commonly used
for examining degeneration and regeneration of axons.
Intraspinal Hemorrhage (Collagenase)
Neutrophil infiltration and ED 1 positive macro-
phages/microglia.
Advantages/disadvantages: not very common.
It is important to note that animal models of SCI pain have
been developed to increase our understanding of depression
(Luedtke et al., 2014) as well as the pain syndrome (Hao and
Xu, 2003). Without a doubt, our knowledge and insight into
SCI from investigations on these animal models has significantly
increased during the last fifteen years. Nonetheless, a number
of limitations have been acknowledged, including the site of
injury. For example, in humans, the predominant location of
injury is at an anterior position and the cervical spine is
typically involved, whereas animal studies are based on the dorsal
side and thoracic spine is functionally deteriorated. Another
disadvantage of using rats is that corticospinal tract lesions
are observed on the dorsal plane, and therefore disability is
limited. Additionally, in humans, the anterior spinal artery,
which transports blood to over 70% of SC tissue, is damaged
or ruptured; on the other hand, the dorsal spinal artery
is impinged upon in animal models of SCI (Akhtar et al.,
2008). Further, laminectomy (invasive techniques which affect
the experimental outcome), anesthesia (neuroprotective; Akhtar
et al., 2008), and gender are all critical to well-planned
studies. Specifically, when using female rats, the researcher
needs to cater for the estrous cycle (metestrus, diestrus,
proestrus and estrus), during which steroid hormones (estrogen
and progesterone) are fluctuating (confounding elements),
and the endocrines are considered to be neuroprotective.
Therefore, the animals need to be synchronized to a specific
phase of the estrous cycle, or to use ovariectomized animals.
Contextually, although rodents are routinely used to simulate
the injuries observed in the clinic, the non-human primate
is undeniably more appropriate for human type of SCIs
(Nesathurai et al., 2006; Akhtar et al., 2008; Nout et al.,
2012).
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FIGURE 2 | Inflammatory milieu produced by secondary injury. An increase in vascular permeability is initiated by hemorrhaging. This is then followed by
extravasation of activated leukocytes, which release inflammatory ligands (such as MMPs to degrade extracellular matrix and intercellular proteins). Interaction
between ferrous iron (Fe2+) and hydrogen peroxide yields hydroxyl radicals (Fenton reaction). Ferric iron (Fe3+) reacts with superoxide to produce oxygen
(Haber-Weiss reaction). Reactive oxygen species (ROS) activates proteins with cysteine-rich residues by structural modification (oxidation, nitration), and to induce
multiple signaling pathways that also modulate gene expression. Intracellular levels of anti-oxidants are depleted in reducing Fe3+ to Fe2+ state. Ultimately, the free
radicals lead to cell and tissue damage, resulting in neuronal and glial necrosis and apoptosis in SC parenchyma. In contrast, beneficial effects are mediated through
subsets of leukocytes and glial cells, which play a crucial role in anti-inflammatory mechanisms.
Different animal models are being used to address multiple
paradigms arising from the devastating trauma of SCI, with the
ultimate aim of being able to ameliorate the suffering of human
subjects. The use of rodents (rats and mice) for experiments on
SC related injuries is on the increase, but transgenic and gene-
deficient, particularly double- and triple-knockout, mice offer
inimitable proposition for focusing studies on specific questions
(Myers et al., 2011, 2014; Fassbender et al., 2012).
INFLAMMATORY ENVIRONMENT
SUBSEQUENT TO PRIMARY INJURY
(SECONDARY INJURY)
In general, inflammation is the body’s adaptive, homeostatic
response to localized-injury, and is instrumental in limiting and
repairing the tissue damage if the compensatory pathways
are still functional. Otherwise, a decompensatory state
follows leading to multi-organ dysregulation and inevitable
death (Popovich et al., 1997; Guízar-Sahagún et al., 2004;
Medzhitov, 2010; David et al., 2012; Allison and Ditor, 2015).
Specifically for SCI, the primary insult inflicted on SC (results
in fracture and/or distortion of the SC, damage to axons,
blood vessels and neurons, including shearing/stretching
of cell membranes) acts as a nexus from which subsequent
temporal-profile of secondary damage emanates, which
may extend to months and years subsequent to the initial
trauma (Table 1, Figures 2, 4). This milieu initiates secondary
injury concomitant with inflammatory cascades arising from
innate (peripheral: neutrophils, monocytes and macrophages;
resident cells of CNS parenchyma: astrocytes and microglia)
and adaptive (B and T lymphocytes) immune responses
(Figures 2, 3, 4). The array of released inflammogens
encapsulates pro-inflammatory cytokines (IFN-γ, TNF-α,
IL-1, IL-6, IL-8 and IL-12)/chemokines (CXCL1, CXCL12),
nitric oxide (iNOS), oxidants, glutaminergic ions, proteases
(matrix metallo-proteinases, calpains, caspases), complement
proteins. Ultimately, the outcome from the action of these
mediators is necrotic and apoptotic cell death with an
impact on functional behavior (autonomic, motor, sensory
and reflex), (Table 1, Figures 2, 3, 4, 5; Popovich et al.,
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1997; Guízar-Sahagún et al., 2004; David et al., 2012;
Allison and Ditor, 2015). In parallel, a compensatory anti-
inflammatory response stemming from same cells with a
different phenotype ensues to repair, be neuroprotective and
neuroregenerative (Cherry et al., 2014; Witcher et al., 2015).
As such, a comprehension of the principal multi-faceted
mechanisms is of paramount importance in facilitating a way
to therapeutic strategies. Hence, in this section, we describe
some of the key players in disseminating the secondary injury,
with a perceptive eye for potential targets for treatment
of SCI.
Hemorrhage
Primary mechanical impact results in immediate localized
changes in vascular tissue as well as a reduction in blood supply
to the area of SCI (Dumont et al., 2001). These alterations rapidly
progress to hemorrhagic and ischemic pathogenesis. The former
is primarily located within the graymatter, while the whitematter
becomes edematous (Tator and Koyanagi, 1997; Mautes et al.,
2000; Losey et al., 2014).
Blood infiltrating into the perivascular space in the gray
matter has been reported to be noxious to parenchymal
cells, eventually leading to neuronal and axonal damage
(Asano, 1980). The internal bleeding initiates multiple
inflammatory events including but not limited to elevated
thrombin formation. This is actually coupled to increased
circulating noradrenaline concentrations which eventually
lead to activation of platelets and therefore thrombogenesis.
It is important to note that upon degradation, components
of hemolysates, the lysed products of red blood cells, will
discharge iron, which is rather toxic (Dumont et al., 2001;
Hua et al., 2006).
Ischemia-Reperfusion Injury
After the mechanical impact of initial injury to the SC and
surrounding tissue, what follows is a prolonged period of
secondary injury. This ensues in phases, which range from
acute (immediately; minutes) to chronic (years; Table 1).
Such injury is primarily caused by hypo-perfused region in
the spinal zone resulting in impairment of the SC (epicenter
and penumbra). This region becomes susceptible to ischemic
damage with breakdown of BSCB. Some hallmarks include
edema, hemorrhaging, endothelial permeability and loss
of autoregulation. These often involve the participation of
multiple components, including different cell types and
biochemical pathways. Disruption of blood flow results
in local cell injury and infarction caused by hypoxia,
ischemia and thrombosis (Fassbender et al., 2011). This
pathological trigger initiates a complex, multi-factorial event
that is facilitated by inflammatory mediators, cell death
(apoptotic, autophagic and necrotic), immune route, oxidative
stress and vascular dysfunction (loss of autoregulation).
This alteration in homeostatic status not only affects the
primary locality of injury but also has an effect on the entire
persona of the individual, encompassing somatic as well as
psychometric derangement (Maldonado Bouchard and Hook,
2014).
Ischemia reperfusion injury is associated with all of the
aforementioned animal models, and is a key player in
inducing a robust immune-response in the affected area
of cord tissue (Zhu et al., 2013). This is characterized
by infiltration of inflammatory cells, such as leukocytes
(macrophages, neutrophils and lymphocytes), astrocytes and
microglia. These activated cells release inflammatory cytokines
and other molecular entities that alter cellular, tissue and organ
homeostasis.
Microglia and Astroglia
Microglial Cells
Neurons (excitable) and glia (non-excitable, astrocytes,
ependymal, oligodendrocytes and microglia) cells constitute
the majority of cellular elements in CNS. The ratio of glia
to neurons is almost equal to one (occupying approximately
50% of the volume of CNS; Azevedo et al., 2009), and glial
cells collectively serve in playing a homeostatic role to support
and protect neurons. Astroglia and microglia choreograph the
innate immune responses of the spinal cord (SC) and brain.
Following a SC trauma (vertebra fractures, displacement),
microglia on sensing cues of cellular or tissue damage (DAMPs,
including myelin and cellular debris, IFN-γ, laminin, or ATP)
via toll-like receptors (TLRs) in their niche (Olson and Miller,
2004; Lee et al., 2007; Lehnardt, 2010; Heiman et al., 2014),
become activated, undergo hypertrophic morphological and
functional changes, as well as transform to a migratory mode
(Witcher et al., 2015). Traditionally, microglial cells (save for
the quiescent state—ramified morphology) exist in two basic
polarised states, which are dependent on external signals,
the M1 (classical activated) pro-inflammatory phenotype and
M2 (alternatively activated) anti-inflammatory phenotype
maintain SC homeostasis (Durafourt et al., 2012). The two
activated phenotypes (M1 and M2) appear with deramification
morphology, being transformed into amoeboid shape (Lee et al.,
2007). Activated M1 microglia, initiate cascades of neurotoxic
responses in secondary phase of SCI, and significantly contribute
to the preponderance of damage (apoptosis and necrosis) to
endothelia, neurons, axons and oligodendrocytes, and finally
phagocytosis (Blight, 1992; Dusart and Schwab, 1994; Sekhon
and Fehlings, 2001; Nguyen et al., 2012). The inflammatory
cascades are channeled through multiple pathophysiological
signaling pathways, including those of cytokines (TNF-α,
IL-1β, IL-6; Rothwell et al., 1997; Pan et al., 2002; Pineau and
Lacroix, 2007), chemokines (Mantovani et al., 2004), iNOS
(Merrill et al., 1993; Matsui et al., 2010), reactive oxygen
species (ROS; Barger et al., 2007), glutamate (Barger et al.,
2007), and proteases (Shields et al., 2000), as illustrated
in Figure 3. The expression of inflammatory cytokines is
evident within two hours from the initial impact of the
mechanical injury (Pan et al., 2002; Pineau and Lacroix, 2007;
Table 1). Further, activated M1 microglia are characterized
by cell surface [such as CD45 (lymphocyte common antigen)
and CD11b (complement receptor 3, integrin αMβ2)] and
intracellular (inducible nitric oxide synthase 2, NOS-2)
markers. In contrast, the anti-inflammatory phenotype M2
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FIGURE 3 | Synopsis of microglia phenotypes (M1 and M2), the two ends of the biological spectrum. Inflammatory cytokines (IL-1β, IL-6, IL-12, IFN-γ,
TNF-α), anti-inflammatory cytokines (IL-4, IL-10, IL-13, TGF-β), chemokines (CCL2, CXCL1, CX3CL1), growth factors (IGF, insulin-like growth factor; BDNF,
brain-derived neurotrophic factor; NGF, nerve growth factor; CNF, ciliary neurotrophic factor; EGF, epidermal growth factor), SP, substance P; NO, nitric oxide; ROS,
reactive oxygen species; O•−2 , superoxide; CGRP, calcitonin gene-related peptide; LPS, lipopolysaccharide; ATP, adenosine triphosphate; Resolvin D1, lipid mediator
derived from docosahexaenoic acid. Also, asterocytes display similar phenotypic polarization.
is symbolized by the release of anti-inflammatory cytokines
(IL-4, Il-10, IL-13), extrinsic (CD206—mannose receptor,
CD163—scavenger receptor) and intrinsic (arginase) biomarkers
(Witcher et al., 2015; Durafourt et al., 2012; Thompson et al.,
2013).
Lipocalin 2 (LCN2), an acute phase protein, displays myriad
of biological functions, which also have an impact on the
CNS (Ferreira et al., 2015; Jha et al., 2015). LCN2 is known
to promote the conversion of microglia in resting state to
M1 phenotype. Moreover, the authors of this investigation
pointed out that M1 polarized microglia secrete LCN2,
which thereby establishes a vicious inflammatory micro-
environment (Jang et al., 2013). In addition, LCN2 not only
suppresses the polarization to M2 phenotype by antagonizing
the phosphorylation of STAT 6 in IL-4 stimulated microglia,
but also sensitizes microglia to auto-death (Lee et al., 2007).
On the other hand, IL-10 polarizes microglia to the protective
M2 phenotype (Thompson et al., 2013). To sum, microglia,
with distinct phenotypes (M1 or M2), regulate the development
and maintenance of inflammatory response in SC. This is
biologically manifested through the release of a complex
and diverse molecular arsenal (detrimental or beneficial)
for neurodegenerative, neuro-protective and neuro-reparative
events.
Polarization into M1 and M2 microglia phenotypes are
the two extreme ends of the spectrum. In between, there is
a continuum of states with cells being defined by unique
molecular signatures (Cherry et al., 2014). Each of these cellular
sub-states takes its cue from the changing micro-milieu, and
responds accordingly by adapting their functional phenotype
to directly target the emerging challenge. However, a recent
study has implied that once the insult is contained, the
microglia subsequently become primed for further stresses with
a more aggressive immuno-inflammatory response (Witcher
et al., 2015). It is feasible that these primed microglia are
probably programmed via epigenetic mechanisms, which are
known to influence various pathologies, such as hypertension
(Al Disi et al., 2015; Anwar et al., 2016a,b), and CNS-
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FIGURE 4 | Schematic illustration displaying primary (cavitation) and secondary lesions, neuronal necrosis, axonal destruction and demyelination
during secondary injury with parenchymal resident cells (reactive astrocytes, microglia), and extravasation of peripheral leukocytes (neutrophils,
monocytes/macrophages, and lymphocytes: B,T and natural killer cells). Wallerian degeneration (microtubules disassembly, microtubule associated protein
degradation by calcium-dependent neutral protease calpain, blebbing of axons, fragmentation and phagocytosis by microglia and macrophages). A small quantity of
Schwann cells are present in CNS, and also they migrate to the CNS from the peripheral nervous system.
related disorders (Sng and Meaney, 2009; Lubin et al.,
2011; Tang et al., 2014). Indeed, epigenetic mechanisms
are recognized to program different SC cell populations
(glial, immune and neuronal; York et al., 2013). Taken
together, this reflects the diversity and functional plasticity,
including the immunoregulatory roles of microglia in SCI.
In order to make use of microglia diversity, a profound
comprehension of regulatory mechanisms is required for
optimum therapeutic strategy, particularly in relation to
neurorepair and neuroregeneration of SC.
Astrocytes
Astrocytes comprise of a heterogeneous population of
cells with diverse functional capacity (Tabata, 2015).
An essential mechanistic operation of these glia cells is
their significant role in maintaining the homeostasis of
CNS (Perea and Araque, 2007; Paixão and Klein, 2010).
In contrast, the astroglia, a component of the innate
immunity system, are considered to be involved in noxious
developments of secondary damage (Table 1). Recent
analyses have revealed the diversity and plasticity that
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FIGURE 5 | Simplified diagram exhibiting the major components of the complement cascade, including regulators of complement activation and
pathophysiological effects.
exists in astroglia reflected by identification of functional
polarization states (classically activated M1 type [synthesize
proinflammatory cytokines, growth factors, NO, glutamate
and reactive oxygen and nitrogen species] and alternatively
activated M2 type [produce anti-inflammatory releasates])
which are dependent on the extracellular environment
for activation. Apparently, the two states are similar to
macrophages and microglial cells (Cherry et al., 2014), and
presumably there may be an array of intermediate states
(Cherry et al., 2014).
Extravasated neutrophils secrete proteolytic enzymes causing
injury to neurons, glia, and endothelial cells (Schwab and
Bartholdi, 1996). Subsequently, macrophages and microglia
are recruited, which not only phagocytose cellular and
molecular debris but contribute to demyelination of axons,
apoptosis of neurons and oligodendrocytes after the initial
insult (Merrill et al., 1993; Shuman et al., 1997; McTigue
and Tripathi, 2008; Hall and Traystman, 2009). At this
stage, regions of cavitation are apparent, and Wallerian
degradation with associated glial scarring (prominence
of astrocytes) is notable (Schwab and Bartholdi, 1996).
Inflammatory environment prompts astrocytes (hypertrophic,
migratory and proliferative) to ring fence the injured area
by formation of a glial scar, which forms a barrier to
regrowth of axons. Interestingly, both microglia (astrocytes
and oligodendrocytes) express inhibitory factors (chondroitin
sulfate proteoglycans, myelin associated glycoprotein, Nogo-A,
oligodendrocyte-myelin glycoprotein and tenascin) to block
axonal regeneration. These are potential targets for therapeutic
manipulation.
It has been promulgated that in both microglia and
astroglia antioxidant exhaustion (glutathione) is induced by
hyperactivity of NADPH oxidase, which elicits excessive
secretion of neurotoxicant glutamate with associated neuronal
and oligodendrocyte loss (Barger et al., 2007; Johnstone et al.,
2013). Activation of NMDA receptors by glutamate triggers
influx of calcium, which is a cofactor activating calpain
(potently degrades axon/myelin), a neutral cysteine protease
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(Shields et al., 2000). Therefore, therapeutically targeting
oxidative enzymes will prevent axonal demyelination, preserve
oligodendrocyte integrity and spare neuronal loss (Johnstone
et al., 2013).
Astrocytes contribute to progression of axonal degradation,
neuronal death and motor/sensory functional deficit following
SCI. Several options are available to therapeutically target
astroglia, such as development of agents that reduce the density
of polarised M1 astroglia in SC, and to increase the anti-
inflammatory M2 type astroglia.
Oxidative Stress
In able-bodied individuals, the activity of oxidative species (free
radicals and ROS) is balanced by cellular anti-oxidant agents.
Chronic levels of ROS accompany many inflammatory diseases,
including hypertension, atherosclerosis, neurodegeneration, IRI
and cancer (D’Autreaux and Toledano, 2007; Yang et al.,
2013). Concerning SCI subjects, a milieu is created that
drives a shift in balance towards oxidative stress (pro-oxidant
state), and along with other cues, this evolves into an
inflammatory pathology (Bains and Hall, 2012). The increase
in oxidative stress is also correlated with progression of
age, but there is a reciprocal decline in concentrations of
antioxidants. Consequently, the severity of SCI rises with age
and is dependent on pro-oxidant/anti-oxidant balance (Shao
et al., 2006). Activated parenchyma (microglia) and leukocytes
(macrophages and neutrophils) are the main sources of ROS
(Bains and Hall, 2012; Figure 2). The principal components
of ROS are the superoxides (O•−2 ), hydroxyl radicals (•OH,
a product of Fenton reaction), hydrogen peroxides (H2O2),
nitric oxide (•NO) and peroxynitrites (ONOO−) amongst
others (Xiong and Hall, 2009; Yang et al., 2013). These
are synthesized by enzyme systems (nicotinamide-adenine
dinucleotide phosphate (NADPH) oxidase, myeloperoxidases,
cyclooxygenase, and xanthine oxidase), both in microglia and
leukocytes (D’Autreaux and Toledano, 2007; Bains and Hall,
2012).
Detrimental effects of oxidative stress pathways commence
immediately after the primary impact of SCI, causing membrane
and cellular damage (Silva et al., 2014). Apparently, the
superoxide O•−2 (Liu et al., 1998) and •OH (Bao and Liu, 2004)
are the principle culprits in contused SCI.
Polyunsaturated fatty acids (arachidonic acid,
docosahexaenoic acid) are targets for free radicals, producing
highly reactive electrophilic aldehydes, such as malondialdehyde
(MDA; (Qian and Liu, 1997), 4-hydroxy-2-nonenal (4-HNE;
(Baldwin et al., 1998) and acrolein (Luo et al., 2005), all
of which are considered as biomarkers of oxidative injury
(Figure 2). Enzymatic (cyclooxygenase) and non-enzymatic
oxidation of arachidonic acid also yield 8-iso-prostaglandin
F2α, which again is a marker of lipid peroxidation (Clausen
et al., 2012). The reactive aldehydes damage the blood
spinal cord barrier (BSCB; Mullick et al., 2002; Ellis, 2007),
causing decrease in cell viability (Ayala et al., 2014) and
hence an increase in vascular permeability (Huber et al.,
2002). Conversely, the lipid peroxidation end products are
inactivated by aldehyde dehydrogenases and other enzymes
such as aldehyde reductases, glutathione S-transferases
(Ellis, 2007; Ayala et al., 2014).
The oxidant reactants are inactivated by intra- and extra-
cellular antioxidant defense systems like the enzymatic
superoxide dismutases (SOD), catalase, glutathione peroxidase,
glutathione reductase, and non-enzymatic antioxidants
(vitamins A, E and C; glutathione; carotenoids and flavonoids;
Bains and Hall, 2012). It has been stressed that the therapeutic
window is time-dependent in SCI, and should be triggered as
early as possible (<3 h), not only to curtail the pathology, but
also to quench the oxidative reactants (Bains and Hall, 2012).
Consequently, anti-oxidative therapy may arrest and reverse the
inflammatory response in SCI.
Nitric Oxide
Nitric oxide (NO) participates in pleiotropic activities as a
mediator of physiological and pathophysiological processes
including immunoregulation (Moncada et al., 1991; Toda et al.,
2009). It is synthesized from arginine by NOS, which exists
in three different isoforms: neuronal (nNOS, NOS-2), the
inducible form (iNOS, NOS-2), and the endothelial enzyme
(eNOS, NOS-3). These isoforms are expressed and located in a
variety of cell types and tissues (Toda et al., 2009; Sheng et al.,
2011).
Activated eNOS releases the vasodilating NO, which
maintains vascular homeostatic signaling by modulating arterial
tone, and hence regulating blood pressure. However, when NO
production is impaired, endothelial cell dysfunction ensues,
leading to cardio- and cerebrovascular diseases (Moncada et al.,
1991; Toda et al., 2009).
Inflammatory cytokines (TNF-α, IFN and IL-1) and
glycosphingolipids are recognized for their induction of
iNOS in a broad spectrum of cell types, including astrocytes,
microglia, macrophages, and neurons (Satake et al., 2000; Beattie,
2004; Toda et al., 2009; Sheng et al., 2011). The quantity of NO
generated by iNOS is normally far in excess of that produced by
other isoforms, and iNOS is highly implicated in inflammatory
processes such as SCI (Conti et al., 2007; Maggio et al., 2012).
iNOS produces excessive amounts of NO molecules which
react with superoxide radicals to generate reactive nitrogen
species (Pannu and Singh, 2006). Activation of such oxidative
microcosm triggers lipid peroxidation, DNA fragmentation and
blockade of mitochondrial respiration. Hence, accumulation
of these pathological pathways leads to the degeneration of
resident cells of parenchyma (Maggio et al., 2012). NO has been
implicated in microglia-dependent demyelination and apoptosis
of neuronal cells (Pannu and Singh, 2006). The situation with the
use of inhibitors for NOS isoforms is complex. Studies with iNOS
blockers (1400W and aminoguanidine) have resulted in further
neuronal/oligodendrocyte deterioration instead of neurological
recovery (Pannu and Singh, 2006). Additional studies into
expression, activity, temporal and spatial distribution of NOS
family of enzymes at the site of SCI are required, particularly in
relation to NO-derived secondary damage. This is to ultimately
achieve an optimum level of NO for physiological homeostasis
and therapeutically targeting the enzymes (Marsala et al., 2007;
Tardivo et al., 2015).
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Fibrinogen
Fibrinogen is an acute phase protein, a member of the clotting
cascade, an orchestrator of other diverse functional activities, and
a biomarker for excess risk of cardiovascular disease (Kamath
and Lip, 2003; Mosesson, 2005; Cray et al., 2009; Jennewein
et al., 2011). Evidence shows it may also play a significant
pro-inflammatory role in secondary injury following primary
SCI (Wu et al., 1994). Coagulation abnormalities, particularly
with modest elevation in plasma fibrinogen concentration,
are associated with SCI (Pahl et al., 1994). Immediately
following SCI, thrombotic activity is a major clinical problem,
which subsides over time with recruitment of the fibrinolytic
pathway (Frisbie, 2006). A clear illustration of fibrinogen’s
role in post-SCI inflammatory process is highlighted by its
activation of microglia cells (Davalos et al., 2012), which are
notoriously pro-inflammatory participants in secondary injury
(Fleming et al., 2006; Zhou et al., 2014). Fibrinogen-triggered
astrocyte-stimulation directs scar formation (Schachtrup et al.,
2010), and it also plays a role in activation of microglial
cells by binding to αMβ2 integrins (Jennewein et al., 2011).
As such, fibrinogen has an important function to do by
modulating the activity of parenchymal cells. Moreover,
fibrinogen promotes homotypic and heterotypic cellular
adhesion and aggregation. Indeed, increasing concentration
of fibrinogen correlates with elevated red cell aggregation
and formation of a rouleaux type structures (Rampling,
1981; Rampling and Challoner, 1983; Anwar et al., 1994).
These structures retard the circulatory flow, especially in
low flow areas of pre-capillary arterioles and post-capillary
venules (McHedlishvili et al., 1999; Pearson and Lipowsky,
2004). This scenario causes low-grade inflammation, a pro-
coagulant state with localized endothelial dysfunction (Zilliacus,
1951; Gavins et al., 2011; Jennewein et al., 2011). Further,
fibrinogen is a potent aggregator of white blood cells and
platelets (Kamath and Lip, 2003), the latter being reported
to have impaired function in SCI individuals, placing these
patients at an increased risk for coronary heart disease
(athero-thrombogenesis; Khan et al., 2011). Furthermore,
fibrinogen binds to stimulated leukocytes (Jennewein et al.,
2011), which initially roll along the lumen wall, then adhere to
endothelial cells, followed by extravasation (trans-endothelial
migration) to the focal area of injury where they exert their
inflammatory and anti-inflammatory functions (Belch et al.,
1998; Kirschenbaum et al., 2004; Lominadze et al., 2010;
Jennewein et al., 2011; Figure 2). Taken together, it becomes
apparent that fibrinogen plays a critical role in SCI pathology,
embracing inflammation, coagulation, hemostasis and cellular
interactions.
Leukocytes
Leukocytes (granulocytes, monocytes/macrophages and
lymphocytes) are recruited to the epicenter of SCI, where they not
only participate in inflammatory SCI-induced events, but are also
involved in limiting and repairing of the pathological damage,
hence imparting an anti-inflammatory effect per se (Figure 4;
Fleming et al., 2006; Zhang and Gensel, 2014). Evidently, there
is mounting recognition for the existence in heterogeneity
related to neuro-inflammation between brain and spinal cord
following an identical mechanical trauma. This is in terms of a
more robust response from activated granulocytes, mononuclear
(B and T cells) and microglia cells in SCI compared to the brain
(Batchelor et al., 2008; Zhang and Gensel, 2014). Neutrophils are
the first inflammatory cells to migrate to the site of injury with
an arsenal of oxidative (NADP oxidase and myeloperoxidase)
and proteolytic enzymes (matrix metalloproteinase-9; MMP-9;
Fleming et al., 2006; Kolaczkowska and Kubes, 2013). Hence,
inhibiting the recruitment of neutrophils and monocytes has
been reported to be beneficial in SCI environment (Lee et al.,
2011). In contrast, a recent report implied that subtypes of
neutrophils encourage recovery from inflammatory pathology
during the secondary phase of SCI following the catastrophic
insult of mechanical forces in primary SCI (Neirinckx et al.,
2014).
Macrophages are divided into twomain subtypes, which upon
activation release bioactive mediators like cytokines, nitric oxide
and eicosanoids. The role of pro- (M1) and anti-inflammatory
(M2) macrophages in SCI is slowly being deciphered in detail
(Zhang and Gensel, 2014). Particular attention is being paid
in relation to the ratio of pro-inflammatory macrophages
(cytokines: IL-1β, IL-6, IL-12, TNF-α) to that of anti-
inflammatory type (IL-10, IL-13) during ischemia and in
resolution of the inflammatory response (Shechter et al., 2009;
Wynn et al., 2013; Brown et al., 2014; Zhou et al., 2014). It
is worth mentioning that these macrophages also have a role
in wound healing. Contextually, there is further subdivision
of M1 and M2 (M2a—involved in wound healing, M2b and
M2c) macrophage phenotypes (Parsa et al., 2012). Further, these
investigators alluded to the importance of macrophage diversity
in terms of individual’s immune susceptibility to inflammation
and resolution (Parsa et al., 2012).
The density of lymphocytes (B and T) in tissue at the location
of SCI is considerably lower than other leukocytes (Bradl et al.,
2005). Once again, there is heterogeneity in distribution of
CD4+ and CD8+ T cells, with CD4+ subset being quantitatively
greater than CD8+ lymphocytes in regions of degenerative rat
SC (Bradl et al., 2005). However, B-lymphocytes are known to
exert complex pathophysiological effects, including facilitating
anti-inflammatory and/or pro-inflammatory actions. In SCI,
elevated concentrations of two cytokines (B-cell-activating
factor, BAFF, and a proliferation-inducing ligand, APRIL) and
B-cell maturation antigen (BCMA) have been associated with
B cells. The latter activates B-cells and the cytokines regulate
SCI-autoimmunity (Saltzman et al., 2013). Hence, these proteins
are plausible targets for neuro-immune management. Hopefully,
in the next few years these dichotomous effects of leukocytes
will be clarified in detail, with further emphasis on pro- and
anti-inflammatory secretagogue fingerprints, which can then be
targeted for therapeutically beneficial effects.
The Complement System
Complement factors, part of the innate immune system,
are emerging as significant players in inflammatory
neuropathogenesis of SCI (Alexander et al., 2008; Peterson
and Anderson, 2014). In contrast, complement is also associated
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with neuroprotection, repair and regeneration (Alexander et al.,
2008; Alawieh et al., 2015). Hence, the proteins display a Janus
face of dual activity, beneficial on one hand and detrimental
on the reverse side. Similarly, complement activity is increased
in experimental models (Galvan et al., 2008), and in sera of
patients with SCI (Rebhun et al., 1991). Further, the factors also
contribute to post-reperfusion recovery (Alawieh et al., 2015).
Therefore, the aforementioned have aroused interest in the use
of complement inhibitors as therapeutic agents in the SCI field.
The complement system comprises of almost 60 protein
members, including activators and inhibitors (Liszewski and
Atkinson, 2015). Briefly, the complement system can be
activated by three different pathways: classical, lectin and
alternative routes (Figure 5). These three pathways initially
converge at C3, and finally at terminal position by the
formation of C5b-9, the cytolytic membrane attack complex
(MAC). Complement proteins C3a and C5a participate in both,
depending on the context, proinflammatory and neuroprotective
role (Figure 5; Woodruff et al., 2010; Merle et al., 2015).
Hence, the activation of the complement cascade results in
amplification of the inflammatory response by many-fold
through the recruitment and activation of the immune system
(adaptive and innate, see Table 1). Endogenously produced
cell membrane-anchored inhibitors protect against complement
activation, thereby playing a role in homeostatic functions.
This diverse group embraces the complement receptor 1
(CR1, and Crry—a rodent homolog of human CR1), decay-
accelerating factor (DAF, CD55) and CD59 (glycosylphosphtidyl
protein), all of which are recognized to play a regulatory
role in complement activation (Figure 5; Merle et al., 2015).
Further, the serum factor H modulates the proteolytic activity
at different points of the complement cascade, and is the
principle regulator of complement protein C3b (Jokiranta et al.,
2000; Wu et al., 2009). Another set of complement factor
H-related proteins, originally considered to be antagonists, but
recent studies have redefined them as activators of complement
proteins (Józsi et al., 2015; Figure 5). Rodents treated with
endogenous inhibitors and complement gene-deficient mice
(factor B, C1q and C3) have demonstrated neuronal protection
subsequent to SCI, and improved sensory and locomotor
functions (Galvan et al., 2008; Brennan et al., 2012; Peterson et al.,
2015).
Accumulated evidence gives credence to the safety and
efficacy of complement protein directed therapeutic agents in
equilibrating this overactive innate immune system. This is
reflected by the application of diverse range of novel inhibitors
directed at different protein constituents of the complement
cascade (Figure 5). Namely, Eculizumab (a monoclonal antibody
targeting protein C5) has been used to treat paroxysmal
nocturnal hemoglobinuria (PNH) patients. Thus, Eculizumab
antagonizes the formation of C5b-9 (MAC), and this effectively
reduces hemolysis in the patients (Rother et al., 2007; Brodsky
et al., 2008). Another protein that has recently been tested on
erythrocytes is TT30 (C3d-targeted C3/C5 convertase inhibitor
(Fridkis-Hareli et al., 2011; Risitano et al., 2012), which prevents
complement-mediated lysis of erythrocytes. More recently, a
small molecule anti-complement agent, Compstatin (a peptide
inhibitor of central complement C3) is generating enormous
amount of excitement in clinical environment to eliminate
complement related diseases (Mastellos et al., 2015). Compstatin
is recognized to block complement activation of RBCs of PNH
patients (Janssen et al., 2007; Risitano et al., 2014). To date, these
tested, safe and efficacious inhibitors have not been applied to
alleviate the impact of traumatic SCI on patients. The horizon is
bright with therapeutic reagents.
Apoptosis
Necrotogenic and apoptogenic mechanisms determine the
dimensions of SC lesion during the time-frame of secondary
injury that follows the primary physical impact of SCI (Beattie
et al., 2000). Apoptosis occurs in the parenchymal cells of SC
that include astrocytes, microglia, oligodendrocytes and neurons
(Beattie et al., 2000). Activation of microglia cells is related to
oligodendrocyte cell death and axon demyelination, which are all
attenuated with application of minocycline, an antibiotic (Beattie
et al., 2000). Indeed, a concomitant recovery in neuro-function is
reported with this treatment (Beattie et al., 2000). Therefore, early
application of anti-apoptotic therapy will be a step in direction to
recovery from secondary injury.
INFLAMMATORY EFFECTS ON
CIRCULATION
Effects on SC Vascular Bed
Continuing from the aforementioned (‘‘Animal Models for SCI’’
Section), the inflammatory cascade has an immediate effect
on SC tissue and the peripheral circulation. Subjects with SCI
are at an increased risk of cardiovascular disturbances that
contribute to approximately 40% of deaths in these individuals
(Garshick et al., 2005). In addition, in a significant proportion
of SCI individuals, hypertension, an inflammatory condition, is a
prevalent cardiovascular risk factor (Lee et al., 2006; Selassie et al.,
2013).
The splanchnic and the skeletal muscle vascular beds account
for over 50% total blood pool, and in case of emergency this
pool of blood is diverted to the cerebral, cardiac and adrenal
circulations. Blood is transported to the SC through branches
arising from the aorta. The vascular tree feeding the SC is
complex and extensive in nature along the length of the cord
(Bosmia et al., 2015). It includes three arteries that cater for
the blood supply to the SC: the anterior spinal artery (conduit
for over 70% of blood supply to the SC; and a branch of
vertebral artery arising from the subclavian artery) and the
paired posterior spinal arteries (Bosmia et al., 2015). The
microcirculation in the cord consists of the sulcal (anterior)
and pial (anterior, in combination with branches of posterior
arteries) arterial networks. However, the microvascular system
(centrifugal) delivers blood to a large portion of gray matter
(mostly neurons) and inner half of the white matter (mostly
myelinated tracts). Furthermore, the pial microarterial bed, in
conjunction with outlets from branches of posterior arteries,
provides blood to the posterior white matter and dorsal horns
(Losey and Anthony, 2014). Interestingly, the gray matter is
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highly vascularized compared to white matter, which has a lower
metabolic rate due to low arterial density (Martirosyan et al.,
2011).
Autoregulation is a notably important and well-developed
regulatory mechanism in the vascular system, especially in
response to high levels of carbon dioxide. However, during
SCI, the autoregulation of hemodynamics in the SC vasculature
becomes dysregulated (Bosmia et al., 2015). In contrast to
the cerebral circulation, there is paucity of data on the
pharmacological response of arteries to vasoactive agents from
different locations of the SC, particularly isolated vessels that
would remove any in situ confounding elements (Tator and
Koyanagi, 1997; Bosmia et al., 2015). In this regard, further
studies are warranted to comprehend how different regions of the
SC respond in health and trauma (inflammation), and this would
potentially help in therapeutically maintaining blood supply to
the injured SC.
Vascular endothelial lining controls physiological properties,
and hence it is not surprising that endothelial impairment
promotes SC injuries (Popa et al., 2010; Fassbender et al.,
2011). Indeed, activation of endothelial NO synthase
(eNOS) releases NO, which regulates vascular tone (Toda
et al., 2009). However, cardiovascular derangement ensues
if the activity/expression of eNOS pathway is impaired.
This happens to be the most common signaling route for
cardiovascular dysfunction throughout the vascular network,
including SCI (West et al., 2013). Endothelial function is
also dependent on endothelial-derived hyperpolarizing factor,
EDHF (Gerber et al., 1998; Félétou and Vanhoutte, 2006),
but to our knowledge no study has been conducted on
this important molecular transducer in the SCI condition.
In the context of inflammogenesis, pro-inflammatory
mediators dampen the generation of EDHF (Kessler et al.,
1999). Further, inflammatory cytokines like TNF-α activate
NADPH oxidase to trigger the release of ROS, which
induces endothelial dysfunction (Gao et al., 2007; Zhang
et al., 2009).
Degree of severity in the inflammatory pathology of SCI is a
distinct determinant of cardiovascular outcome, not only in the
SC vascular bed (Martirosyan et al., 2011; Sharma, 2011), but
also the peripheral circulation (West et al., 2013). Abnormalities
associated with SC circulation have been implicated in stroke,
which is an inflammatory condition as well (Popa et al., 2010;
Sharma, 2011). Therefore, therapeutic strategies aimed at the
early stage of inflammatory activation in the microcirculatory
network of SCI patients are pivotal to neuroprotection (Sharma,
2011).
Effects on Peripheral Circulatory Network
An alteration in vascular function, particularly below the
cord lesion, is a key event in inflammogenesis of secondary
injury. This includes ischemic injury that sets in motion an
array of pathological pathways. Inflammatory biodegradation
of the cord-blood barrier further exacerbates the pathology
of secondary injury (hemorrhaging, vascular permeability
and edema). Moreover, the systemic, specifically peripheral,
circulation is profoundly affected (West et al., 2013).
Interestingly, the dysfunction in vascular reactivity observed in
lower limbs, reflected by decreased flow mediated dilatation,
is greater compared to the upper limbs of SCI patients (Stoner
et al., 2006). Similarly, it has been suggested that compromised
blood flow in dermal arterioles results in skin lesions, a further
indicator of altered blood flow in SCI individuals (Deitrick
et al., 2007). Contextually, the normalized intima-media
thickness of lower-extremity arteries (superficial femoral and
popliteal arteries, structural inward remodeling) is greater
in SCI individuals than a healthy able-bodied control group
PAD (Bell et al., 2011). This is indicative of subclinical
prevalence of lower limb peripheral arterial disease, PAD
(Bell et al., 2011). As a matter of fact, PAD is partially driven
by an altered lipid profile in these subjects (Bauman and
Spungen, 1994). Interestingly, investigators have reported a
greater incidence of lower limb PAD associated with higher
burden of stroke (Criqui et al., 1992). The afore-mentioned
offers an explanation for the observation that patients with
SCI are at an increased risk of future ischemic stroke (Wu
et al., 2012). Therefore, examining double insults in rats,
such as an initial SCI event followed by middle cerebral
artery occlusion (MCAO) procedure may be considered a
suitable model for a prospective stroke development. Further,
thoracic SC sectioning in rats is associated with decrease in
microvascular blood flow in several organs, including the
liver, spleen and muscle. Apparently, these changes correlate
with increase in peripheral arterial resistances, and hence
a cause for future organ failure (Guízar-Sahagún et al.,
2004).
In conjunction with SCI, the circulatory disturbances may
be even more pronounced in the prior presence of established
risk factors, such as diabetes, obesity, dyslipidemia, tobacco
abuse, alcohol, low self-appreciation or economic well-being,
malnutrition, and hypertension. All of which are associated
with an inflammatory pathology, where in most cases the
microvascular network is already compromised (Granger et al.,
2010). Evidently, to our knowledge, no studies have taken
place to address these plausible factors in pathophysiology
of SCI. However, it has been suggested that patients with
SCI demonstrate a distinct physiological profile relative to
healthy, able-bodied controls (Wilt et al., 2008). Apparently,
an adverse serum lipid profile is a common problem in SCI
patients compared to ambulatory controls (Gilbert et al., 2014;
Lieberman et al., 2014). This is specifically related to low
levels of high density lipoprotein cholesterol, HDL-C (Gilbert
et al., 2014; Lieberman et al., 2014). The aforementioned
investigations suggest that high quality intervention studies
incorporating prior risk factors for CVD must be forthcoming
to comprehend and build up an overall picture for SCI
individuals.
Inflammatory Role of Renin/Angiotensin
System in SCI
The balance between angiotensin converting enzyme (ACE)
and ACE2 of renin angiotensin system (RAS) pathways is of
considerable importance for homeostasis in the whole body.
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The sustained shift in equilibrium towards ACE results in a
pathologic state, which often arises in SCI (Groothuis et al.,
2010; Popa et al., 2010; Al Dera and Brock, 2015). This leads to
stimulation of a network of transducing pathways, including an
increase in Ang II-induced vasoconstriction, Ang II-stimulated
oxidative stress, as well as cellular proliferation. All of these
mechanisms contribute to Ang II-derived inflammation, which
in turn participates in secondary injury (Groothuis et al., 2010;
Vajapey et al., 2014; Al Dera and Brock, 2015). However, the
ACE2/Ang 1-7/Mas route is considered to be neuroprotective
(Bennion et al., 2015). At any rate, further studies are needed
to better determine the role of RAS in the inflammogenesis
of SCI.
Effects on Rheological Parameters
Hemodynamic factors are important participants in various
pathologies including secondary SCI. The determinants of
whole blood viscosity include plasma viscosity, erythrocyte and
leukocyte aggregation (rouleaux), and red and white blood cell
deformability (Hochmuth, 1993; Anwar et al., 1994; Adams
and Nash, 1996; Rampling et al., 2004). Plasma viscosity and
red cell aggregation are a function of plasma proteins (large,
asymmetric), particularly fibrinogen, immunoglobulins (IgM,
IgA and IgG), alpha-2-macroglobulin and lipoproteins (Anwar
and Rampling, 2003). As indicated earlier, inflammation
progressively increases the activation of white blood cells, and
decreases white blood cell deformability. Consequentially, the
transit time through the circulatory network is significantly
increased when an activated, and hence less deformable leukocyte
(8 µm, nucleated), which is more than a 1000 times less flexible
than an erythrocyte (anucleated), circumnavigates through
the capillary network, particularly vessels of dimension 3 µm in
diameter (Hochmuth, 1993; Adams and Nash, 1996; Anwar et al.,
1999). Leukocytes alter hemodynamics by plugging capillaries
in the microcirculation (Adams and Nash, 1996; Anwar et al.,
1999).
In a rabbit model of SC ischemia reperfusion injury, a number
of observed determinants of hemo-rheological abnormalities,
including whole blood viscosity, plasma viscosity, red cell
aggregation are increased, whereas erythrocyte deformability is
reduced (Zhang et al., 2012). Treatment with Tanshinone-II A
sulfonate, a derivative of Salvia miltiorrhiza, of IRI improved all
the rheological parameters (Zhang et al., 2012). Apart from this
single study (Zhang et al., 2012), there is a clear lack of data
with regards to hemo-rheological properties in SCI injury. This is
surprising as there is a strong relationship between inflammatory
processes and hemo-rheological parameters (Rampling, 1998).
Indeed, inflammation drives leukocyte stimulation (becoming
adhesive, poorly deformable, releasing proteolytic enzymes) and
activates the clotting cascade. Together, these changes lead to
fibrinogen heterogeneity, and hence alteration in rheological
properties of blood (Rampling, 1998). Moreover, viscometric
resistance is a contributory factor to total peripheral resistance
that is a significant variable affecting blood pressure. Both
hemo-rheological and vascular complications may, therefore, be
implicated in observations regarding blood pressure oscillations
in earlier and later stages of SCI (West et al., 2013).
NOVEL THERAPEUTIC STRATEGIES FOR
AMELIORATING SCI BURDEN
Methylprednisolone (MP), a synthetic glucocorticoid, remains
the mainstay for treatment of SCI. This stems mainly from
the anti-inflammatory nature of the drug and protection from
peroxidation of membrane lipids (Bracken, 2001). But, the
corticosteroid suffers from a major short-coming in that of
neurological competence, such as lack of neurite sprouting and
remyelination of spared axons, and hence a deficit in functional
recovery (Constantini and Young, 1994; Ito et al., 2009). In
addition, the associated detrimental side-effects of the steroid
(gastrointestinal bleeding, pulmonary complications, and sepsis),
particularly at high doses of MP, outweigh its primary beneficial
property (Ito et al., 2009). From the preceding sections, it
becomes evident that in the adult primate CNS, the mature
neurons and oligodendrocytes are terminally differentiated as
well as inherently devoid of proliferative processes due to
inability to produce growth-promoting chemicals (Rakic, 1985;
Bhardwaj et al., 2006; Nowakowski, 2006; McTigue and Tripathi,
2008); and the capacity to divide is limited to progenitor/stem
cells (Gonzalez-Perez and Alvarez-Buylla, 2011; El Waly et al.,
2014). Consequently, for a therapeutic strategy to be potentially
effective in alleviating SCI (inflammatory neuro-degeneration),
it must demonstrate multiple capacity to be anti-inflammatory,
neuro-protective, and neuro-restorative. In this section, we have
incorporated some of the treatment approaches that have yielded
encouraging results from the lab with potential for translation
to the bedside. Moreover, the same modalities are provided in
a tabular form to illustrate their application in clinical trials
(Table 2).
Exercise
Following the mechanical impact in causing primary SCI,
the secondary damage is responsible for activation of diverse
pathophysiological effects and one of the most profound
outcomes is the loss in behavioral function, specifically the
inability to ambulate. A distinct advantage of exercise is not
only that of non-invasive therapy, but as an elixir of well-being,
both physical and in terms of psyche of the individual. Exercise
imparts positive effects on muscle mass, reduces osteoporosis,
and improves cardiovascular endurance and quality of life.
Also, it improves the physiology and mood of patients with SC
dysfunction through neuroprotective means, neuroregenerative
processes and rehabilitative methods, all leading to functional
recovery (Sandrow-Feinberg and Houlé, 2015). In a rat model of
contusion injury followed by treadmill exercise (duration period
of 6 weeks) resulted in suppression of apoptosis (ratio of B-cell
lymphoma (Bcl-2) to Bax, and reduced caspase-3 expression).
Concomitantly, the activation of PI3K/Akt survival pathway
raised the expression of neurotrophic factors (neurotrophin-3,
nerve growth factor and insulin-like growth factor). Together,
these effects contributed to recovery of motor function (Jung
et al., 2014). Exercise is advocated as one of the foremost
rehabilitative therapies for SCI, particularly in promoting
locomotor capacity; and this has paved the way for conducting
clinical trials (Table 2).
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TABLE 2 | An outline of therapeutic modalities (cell-based, exercise and pharmacological agents), their biological effects, and clinical trials for the
treatment of SCI.
Therapeutic
modulator
Biological actions Status Study title Clinicaltrials.gov
Identifier
Exercise Increases skeletal muscle mass
as well as cellular, biochemical,
and cardiovascular functions;
Improves neuroprotection,
regeneration and rehabilitative
processes
Currently
recruiting
participants
Study about acting of adaptive sport
in musculoskeletal, cardiovascular
system and the quality of life of
individuals with spinal cord injury
through biomedical instrumentation
NCT02177929
Minocycline Neuroprotective, functional recovery,
tissue sparing, down-regulation of
pro-inflammatory species
Recruiting Phase III study of minocycline
in acute spinal cord injury
NCT01828203
Cethrin (BA-210) Inhibitor of Rho/ROCK signaling;
reduced apoptosis; decreased glial
scarring; regenerative growth of axons
Completed A safety study for cethrin (BA-210) in
the treatment of acute thoracic
and cervical spinal
NCT00500812
Erythropoietin Anti-apoptogenic;
anti-inflammatory;
improves vascular integrity
Suspended
participant
recruitment
Evaluation of the tolerability
and efficacy of erythropoietin (EPO)
treatment in spinal shock:
comparative study vs.
methylprednisolone (MP)
NCT00561067
Riluzole Blocks [Na+] influx; inhibits
glutamatergic neurotransmission;
and improves neurological outcome
Currently
recruiting
participants
Riluzole in spinal cord
injury study (RISCIS)
NCT01597518
Hypothermia Reduces anti-inflammatory species;
decreases microglia activation;
suppresses neurotoxicity and
mitigates blood spinal cord
barrier disruption; Anti-apoptogenic
Currently
recruiting
participants
Hypothermia following acute
spinal cord injury
NCT01739010
Cellular approach:
macrophages
Phagocytosis of cell debris;
regeneration of axons; and
neurological benefits
Suspended
participant
recruitment
A Phase II multicenter, randomized-
controlled study to evaluate the
safety and efficacy of autologous
incubated macrophages for the
treatment of patients
with complete spinal cord injuries
NCT00073853
Cellular approach:
bone marrow derived
mesenchymal stem cells
Promote neuronal regeneration;
provide neuroprotection;
replace neurons;
and neurotrophic factors
Completed Cell transplant in spinal cord injury
Patients
NCT00816803
Minocycline
Minocycline (tetracycline antibiotic analog) suppresses
microglial activation, and thereby attenuates neuroinflammation
in rat contusion injury. In addition, reduced apoptogenesis of
oligodendrocytes was associated with suppression of pro-nerve
growth factor synthesis in microglia, both in vivo and in vitro, as
a consequence of antagonism of p38 mitogen-activated protein
kinase activation. Also, in the same study minocycline blocked
the expression of p75 neurotrophin receptor as well as RhoA
activation. Collectively, an improvement in functional recovery
was noted (Yune et al., 2007). In addition, administration of
minocycline to experimental models of SCI led to an elevation
in levels of IL-10, which is characterized by anti-inflammatory
properties (Thompson et al., 2013). Similarly, minocycline
by inhibiting microglial activation and proliferation not only
improves the integrity and viability of BSCB (Festoff et al., 2006;
Yenari et al., 2006), but also reduces neuronal and glial apoptosis,
leading to functional outcome improvements following SCI in
experimental models and preclinical studies (Stirling et al.,
2004; Festoff et al., 2006; Casha et al., 2012). The biological
improvements implied by investigations on minocycline have
been stepped-up to clinical trials status (Table 2).
Cethrin (BA-210)
Following SCI, upstream signaling proteins (axonal growth
inhibitors) activate Rho, which on binding to GTP is an
activator of Rho-associated coiled-coil kinase (Rho-kinase,
Rho/ROCK, serine/threonine kinases; Julian and Olson, 2014).
ROCK exists in two isoforms ROCK1 and ROCK2, the
expression of latter is 2-fold greater than ROCK1 in CNS
(Julian and Olson, 2014). ROCK2 transduces inhibitory signals
through modulation of actin cytoskeleton dynamics to block
axonal regeneration (Julian and Olson, 2014). Therefore, it
is not surprising that transducers Rho-kinases (ROCK1 and
ROCK2) have been identified as therapeutic targets in SCI.
A number of inactivators of this signaling route have been
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reportedly used in the clinic and different animal models
of SCIs in rats, including Cethrin (BA-210), fasudil and Y-
27632. The inhibitors of Rho-kinases promote SCI axonal
regeneration and improved locomotor recovery (Lord-Fontaine
et al., 2008; McKerracher and Anderson, 2013; Watzlawick et al.,
2014).
Erythropoietin
Erythropoietin (EPO), a glycoprotein, regulates erythropoiesis,
and is prescribed for the treatment of anemia (Eschbach et al.,
1987; Jelkmann, 2011). The erythropoietin receptor (EPO-R)
is expressed in the CNS, including neurons and glial cells
(Nagai et al., 2001; Lombardero et al., 2011). This cytokine
has long been recognized as a neuroprotectant by inducing
non-hematopoietic effects through suppression of inflammation,
utilizing anti-apoptogenic pathways, restricting oxidative stress,
and improving vascular integrity (Gorio et al., 2002; Mofidi et al.,
2011; Simon et al., 2011). Moreover, it possesses neurorestorative
properties (Mofidi et al., 2011). Further, EPO has been shown
to reduce lesion size, improve structural and functional recovery
in the SCI condition, and the benefits have been observed in
both animal and human studies (Gorio et al., 2002; King et al.,
2007; Simon et al., 2011). However, there are several drawbacks
with the use of EPO, such as the increase in hematocrit,
which increases blood pressure, and thrombotic complications
(Jelkmann, 2011; Lombardero et al., 2011). In order tomove away
from these negative aspects, investigators have resorted to the use
of non-erythropoietic EPO structural variants like carbamylated
EPO and asialo-EPO (King et al., 2007; Mofidi et al., 2011; Chen
et al., 2015).
Riluzole
In SCI, persistent stimulation of neuronal voltage-dependent
sodium ions channels induces enhanced rates of cell death,
arising from acidosis, cellular swelling and glutamatergic
toxicity (Wilson and Fehlings, 2014). Riluzole (2-amino-6-
[trifluoromethoxy]benzothiazole) is approved by the USA.
Food and Drug Administration (FDA) for the treatment
of amyotrophic lateral sclerosis (Fehlings et al., 2016). A
phase 1 trial of riluzole divulged data on pharmacokinetics,
safety, tolerance at the administered dose, and concluded with
positive neurological outcomes (Chow et al., 2012). Riluzole
is acknowledged to transduce several mechanistic pathways
to ameliorate SCI. The benzothiazolic agent mitigates neural
glutamatergic-excitotoxicity by inhibiting the interaction
between excitatory amino acid glutamate with its consonant
glutamate receptor. Also, riluzole blockades voltage-dependent
calcium and sodium channels, attenuates apoptosis and
inflammation. Collectively, the outcome emanating from these
different mechanisms is the sparing of neurological tissue and
that has a beneficial effect on functional recovery following SCIs
(Hama and Sagen, 2011; Wu et al., 2013; Wilson and Fehlings,
2014). Further, experimental data indicates that riluzole may be
a remedy for neuropathic SCI pain too (Hama and Sagen, 2011).
The success of riluzole-driven experimental and preclinical
studies has been at the cornerstone for progression of the drug
onto Phase 2/3 clinical trials for patients with SCI (Fehlings et al.,
2016; Table 2).
Hyperthermia
Application of modest hypothermia (33◦C) as a treatment
following SCI has managed to garner interest as a consequence
of beneficial effects in promoting functional recovery, both in
preclinical models and clinical setting (Dietrich, 2009; Lo et al.,
2009; Levi et al., 2010). In the rat cervical model of contusive SCI,
systemic hypothermia enhanced preservation of tissues (axonal
sparing) with prevention of locomotor disability, and augmented
skeletal muscle strength (Lo et al., 2009). These promising results
have set the stage for application of this technique in clinical trials
(Table 2).
Ibudilast
In co-cultures of neurons and microglial cells, increasing
doses of ibudilast, non-selective phosphodiesterase (PDE)
inhibitor, decrease neuronal cell death induced by activation
of microglia with a combination of lipopolysaccharide (LPS)
and IFN-γ. Neuroprotective effect was caused by modulation
of inflammatory mediators within activated microglial cells.
The Investigators observed reduction in pro-inflammatory
cytokines (IL-1β, Il-6 and TNF-γ), suppression of enzymatic
activities of iNOS (decrease in synthesis of NO) and NADPH
oxidase (reduced production of ROS). In contrast, an
augmented secretion of the anti-inflammatory cytokines (IL-10)
and neurotrophic factors (nerve growth factor, glia-derived
neurotrophic factor, and neurotrophin-4) was observed.
Therefore, ibudilast spares neurons from destruction, and
reduces the stimulation of microglia (Mizuno et al., 2004). In
addition to the preceding beneficial effects, the PDE-antagonist
is also effective in controlling neuropathic pain that is presumed
to be effective through suppression of activation of innate
immune cells (astroglia and microglia; Ledeboer et al., 2007;
Walters, 2014).
Cytotherapy
In different animal models of SCI, a diverse group of cells are
under investigation as a therapeutic tool to lower the burden of
secondary injury. The cells being transplanted include the glial
cells, mesenchymal stromal cells, neural stem cells, pluripotent
stem cells, and Schwann cells (El Waly et al., 2014; All et al.,
2015; Sabapathy et al., 2015). The successful outcome of cell
therapy in experimental models of SCI has raised optimism for
these procedures to be translated to the clinic, and hence towards
neurobehavioral/ambulatory functional recovery of SCI patients.
We illustrate this with two examples of cellular application in SCI
scenario.
Macrophages
Individual variation in immune responses to comparable
type of SCI is a reflection of the presence of distinct
macrophage phenotype, either M1 or M2. This thesis was
related to the serum levels of pro-inflammatory (M1) or anti-
inflammatory/protective (M2) cytokines/chemokines profiles
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after SCI. The authors suggested the application of this
difference can be utilized for the management of acute SCI
and neurorehabilitation (Huang et al., 2014). In an earlier
study, incubated autologous macrophages promoted locomotion
recovery in different rat models of SCI (contusion and
transaction). Also, the use of these in vitro cultured macrophages
for cell-therapy is relatively safe and efficacious as regard to the
end-point. Specifically, recovery of sensory/locomotor function
in patients, and can be considered as advancement in the
treatment of SCI (Knoller et al., 2005).
Bone Marrow-Derived Mesenchymal Stem Cells
Intravenously administered rat bone-marrow-derived
mesenchymal stem cells (BMMSCs) decreased cavitation
volume in BMMSCc-treated rats with contused SCs, and
expression of markers for neuronal and glial cells. Functional
recovery was more evident when cells were applied within 6 h
post-SCI (Osaka et al., 2010). These results are in line with
other studies showing significant recovery in locomotor function
(Oliveri et al., 2014).
To sum, motivated by positive results from experimental
and human studies, investigators have initiated clinical trials
based on the aforementioned therapeutic modalities to go
beyond the therapeutic administration of MP or in combination
with other treatments; and for further information these are
cited at http://www.clinicaltrials.gov (USA National Institutes of
Health website). In Table 2 are displayed a group of clinical trials
that are in progress to examine therapeutic efficacy of cell therapy
and pharmacological agents for treatment of SCI.
CONCLUSION AND PERSPECTIVES
To conclude, multi-factorial inflammatory processes are the
driving force responsible for the secondary injury following
primary insult of SCI. The deleterious actions arising from
inflammation are complex, and the mechanisms have been
incompletely characterized. As expressed above, diverse
responses in the neurovascular compartment of SC trigger
secondary injury, including, but not limited to, ischemia
reperfusion injury. This milieu leads to activation of leukocytes
and SC parenchymal cells, resulting in shift in balance towards
inflammatory cells. Constituents of this inflammatory phenotype
are amplified oxidative stress, pro-inflammatory cytokines
and chemokines, NO system derangement, stimulation of
the complement cascade, and impaired endothelial barrier
function, eventually leading to axonal and neural degeneration,
demyelination and enhanced thrombosis. Collectively, the
degree of inflammation is associated with severity and functional
decline in SCI patients.
MP, a synthetic glucocorticoid agent, remains the first-line
drug of choice for treatment of SCI, and to-date no other
medication for SCI therapy has been successfully translated from
the bench to the bedside. Therefore, novel therapeutic targets
need to be explored. Because of the heterogeneity of secondary
injury, a combinatory therapeutic approachmay have the desired
goal. Application of pharmacological treatment at the earliest
will mitigate the deleterious effects of full-blown inflammatory
cascades associated with secondary injury. Hence, this action
would not only preserve the SC tissue (neural and vascular), but
may also aid in functional recovery. However, optimal treatment
modalities will only be attained by a profound understanding of
inflammatory mechanisms, which are yet to be precisely defined.
For this to happen, it is imperative that further studies are
conducted in the laboratory as well as in a large set of SCI patient
groups at multi-centers, worldwide. It is critical to note that these
patient groups ought to encompass age, gender (including pre-
and post-menopausal groups) and ethnicity, as well as the three
major scourges of humans in 21st century: hypertension, obesity
and diabetes. The data obtained from multiple bio-systems
through experimental and human investigations will likely help
in identifying unique molecular fingerprints as biomarkers,
which may be therapeutically targeted in the near future.
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